Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005659700
Thu, 20.04.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 20 April 2023 - Eckert & Ziegler Radiopharma GmbH, a subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), has received the manufacturing authorization for Lutetium-177 (non-carrier-added Lu-177) in GMP grade from the competent German authority. The approval is the basis for the marketing author [ … ]
Wed, 12.04.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 12 April 2023 – Eckert & Ziegler’s fully owned subsidiary Qi Kang Medical Technology Ltd. (QKM) has recently received the authorization for its Environmental Impact Assessment (EIA) from the Department of Ecology and Environment of Jiangsu Province in China. The responsible authorities approved QKM’s planned construction of a radioisoto [ … ]
Wed, 12.04.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 12 April 2023 – Eckert & Ziegler’s fully owned subsidiary Qi Kang Medical Technology Ltd. (QKM) has recently received the authorization for its Environmental Impact Assessment (EIA) from the Department of Ecology and Environment of Jiangsu Province in China. The responsible authorities approved QKM’s planned construction of a radioisoto [ … ]
Tue, 04.04.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, Germany and Indianapolis, Indiana, USA – 4 April 2023 – Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (“POINT”, NASDAQ: PNT) have signed an agreement on the supply of Actinium-225 (non-carrier-added Ac-225). Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POIN [ … ]
Tue, 04.04.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, Germany and Indianapolis, Indiana, USA – 4 April 2023 – Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. (“POINT”, NASDAQ: PNT) have signed an agreement on the supply of Actinium-225 (non-carrier-added Ac-225). Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POIN [ … ]
Thu, 30.03.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 30 March 2023 - Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) achieved sales of € 222.3 million in FY 2022. Compared to the previous year, sales increased by € 41.9 million or 23%. Net income reached € 29.3 million, thus increasing by nearly 20% compared to the previous year's figure adjusted for special effects.
In the Isotope Produ [ … ]
Thu, 30.03.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 30 March 2023 - Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) achieved sales of € 222.3 million in FY 2022. Compared to the previous year, sales increased by € 41.9 million or 23%. Net income reached € 29.3 million, thus increasing by nearly 20% compared to the previous year's figure adjusted for special effects.
In the Isotope Produ [ … ]
Fri, 24.03.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 24 March 2023. The Executive Board and Supervisory Board of Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) have decided to prepare the conversion of the company into a European Company (Societas Europaea, SE) by changing its legal form. The dualistic management system, consisting of an Executive Board as the management body and a Super [ … ]
Fri, 24.03.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 24 March 2023. The Executive Board and Supervisory Board of Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) have decided to prepare the conversion of the company into a European Company (Societas Europaea, SE) by changing its legal form. The dualistic management system, consisting of an Executive Board as the management body and a Super [ … ]
Thu, 23.03.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 23 March 2023 - Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) closed FY 2022 with sales of 222.3 million EUR. Net income for the year rose by around 20% compared to the previous year's figure adjusted for special effects and reached 29.3 million EUR, which corresponds to earnings per share of 1.41 EUR. Based on these figures, Executiv [ … ]